reports
Helix Biopharma Corp: 1 director
A director at Helix Biopharma Corp maiden bought 21,009,229 shares at 0.950CAD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
REGN REGENERON PHARMACEUTICALS INC.
PRFT PERFICIENT INC.
MSI MOTOROLA SOLUTIONS INC.
HRL HORMEL FOODS CORPORATION
EXTR EXTREME NETWORKS INC.
DHX DHI GROUP
CVS CVS HEALTH CORPORATION
CTG COMPUTER TASK GROUP INC.
CPSS CONSUMER PORTFOLIO SERVICES INC.
CIEN CIENA CORPORATION
ACAD ACADIA PHARMACEUTICALS INC.
MCK MCKESSON CORPORATION
HBP. HELIX BIOPHARMA CORP.
BLDR BUILDERS FIRSTSOURCE INC.
TR TOOTSIE ROLL INDUSTRIES INC.
BXC BLUELINX HOLDINGS
TRNS TRANSCAT
AA ALCOA CORPORATION
PI IMPINJ INC.
ABBV ABBVIE INC.
VNCE VINCE HOLDING
OPNT OPIANT PHARMACEUTICALS
ARLO ARLO TECHNOLOGIES
HOV HOVNANIAN ENTERPRISES INC. CLASS A
BSIG BRIGHTSPHERE INVESTMENT GROUP INC.
MRBK MERIDIAN
OCN OCWEN FINANCIAL CORP.
AUID IPSIDY
LEE INC.
LEE ENTERPRISES INC
Helix Biopharma Corp. Announces Fiscal Third Quarter 2020 Results
Helix Biopharma Corp. Announces Fiscal Third Quarter 2020 Results RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2020. OVERVIEW The Company reported a consolidated net loss and total comprehensive loss of $2,594,000 ($0.02 loss per common share) and $7,060,000 ($0.05 loss per common share), respectively for the three and nine-month period ended April 30, 2020. ...
Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third...
Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results RICHMOND HILL, Ontario, July 13, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that, further to its news release dated June 11, 2020, it intends to file its interim consolidated financial statements for the three and nine month periods ended April 30, 2020, related management’s discussion and analysis (“MD&A”) and related management certific...
Helix BioPharma Corp. to divest remaining ownership of Polish subsidia...
Helix BioPharma Corp. to divest remaining ownership of Polish subsidiary RICHMOND HILL, Ontario, June 26, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has entered into a non-binding term sheet to divest the remaining shares it holds in its Polish subsidiary (the “Divestment”), Helix Immuno-Oncology S.A. (“HIO”), representing approximately 51% of the issued and outstandi...
Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor...
Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual Investor Forum on June 23, 2020. Dr. Heman Chao, Chief Executive Officer of Helix is scheduled to present on Tuesday, June 23rd at approximately 1:20pm Eastern Time. The presentation will be webcast live on the confer...
Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third...
Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results RICHMOND HILL, Ontario, June 11, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that it intends to rely on exemptions granted in Ontario Instrument 51-505 Temporary Exemption from Certain Corporate Finance Requirements (the “Blanket Relief”) to extend the deadline for filing its interim consolidated financial statements for the three and nine...
Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be rel...
Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020 RICHMOND HILL, Ontario, May 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO 2020 Annual Conference. The ASCO publi...
Helix BioPharma Corp. Provides Corporate Update
Helix BioPharma Corp. Provides Corporate Update RICHMOND HILL, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today provides a corporate update. COVID-19 As countries across the globe face an unprecedented public health crisis due to COVID-19, Helix has taken various measures to protect the health and well-being of our staff while maintaining business continuity. The office and laboratory of Helix in Canada have been foll...
HELIX BIOPHARMA CORP. ANNOUNCES FISCAL SECOND QUARTER 2020 RESULTS
HELIX BIOPHARMA CORP. ANNOUNCES FISCAL SECOND QUARTER 2020 RESULTS RICHMOND HILL, Ontario, March 16, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2020. OVERVIEW The Company reported a consolidated net loss and total comprehensive loss, including non-controlling interest of $2,255,000 ($0.02 loss per common share) and $4,466,000 ($0.04 loss per common share), respectively for the three and...
Helix BioPharma Corp. Closes $6.0 Million Private Placement
Helix BioPharma Corp. Closes $6.0 Million Private Placement RICHMOND HILL, Ontario, March 12, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 5,042,016 units of the Company (“Units”) at a price of $1.0332 per Unit, and the concurrent disposition of 1,708,023 shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), to a third-party purchaser, representing an 1...
Helix BioPharma Corp. to Present at the Noble Capital Markets’ Sixt...
Helix BioPharma Corp. to Present at the Noble Capital Markets’ Sixteenth Annual Investor Conference RICHMOND HILL, Ontario, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Heman Chao, Helix’s Chief Executive Officer, will be presenting at NobleCon - Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida - on Monday, February 17th at 3:00PM Eastern Stand...
Helix BioPharma Corp. Closes $3.0 Million Private Placement
Helix BioPharma Corp. Closes $3.0 Million Private Placement RICHMOND HILL, Ontario, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 2,940,000 units of the Company (“Units”) and the disposition of shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), representing an 8.5% stake in HIO (together with the Units, the “Purchased Securities”) for aggrega...
Helix BioPharma Corp. to Present at the Biotech Showcase Conference in...
Helix BioPharma Corp. to Present at the Biotech Showcase Conference in San Francisco RICHMOND HILL, Ontario, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Tuesday, January 14, 2020 at 11:00am (PT) at Hilton San Francisco Union Square. Biotech Showcase Conference, produced by Demy-Colton and EBD Group, is an investor and networking conference devo...
Helix BioPharma Corp. Announces Fiscal First Quarter 2020 Results
Helix BioPharma Corp. Announces Fiscal First Quarter 2020 Results RICHMOND HILL, Ontario, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2020 ending October 31, 2019. OVERVIEW The Company recorded a net loss and total comprehensive loss, including non-controlling interest of $2,211,000 ($0.02 loss per common share) and $1,379,000 ($0.01 loss per common share) for the three-month periods e...
Helix BioPharma Corp. Commences L-DOS47 Phase lb/ll Pancreatic Cancer ...
Helix BioPharma Corp. Commences L-DOS47 Phase lb/ll Pancreatic Cancer Clinical Study RICHMOND HILL, Ontario, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the start of enrollment and screening in the Company’s Phase lb/ll clinical development program for previously treated patients with advanced pancreatic cancer. The study is entitled “A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 plus Dox...
Helix BioPharma Corp. Reports Voting Results
Helix BioPharma Corp. Reports Voting Results RICHMOND HILL, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on December 6, 2019 (the “Meeting”). In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the Meeting. There w...
Helix BioPharma Corp. Announces Fiscal 2019 Year-End Results
Helix BioPharma Corp. Announces Fiscal 2019 Year-End Results RICHMOND HILL, Ontario, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2019. FINANCIAL REVIEW The Company recorded a net loss and total comprehensive loss of $7,526,000 and $8,625,000 (a loss per common share of $0.07 and $0.09) for the fiscal years ended July 31, 2019 and 2018 respectively. Research and development Research and development...
Helix BioPharma Corp. Board Changes
Helix BioPharma Corp. Board Changes RICHMOND HILL, Ontario, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors. The Board has accepted the resignation of Mr. Sylwester Cacek’s as director of the Company, effective October 9, 2019. In his place, the Board is pleased to announce the appointment of Mr. Ireneusz Fąfara to the Company’s Board. Mr. Fąfara has over 30 years of finan...
Helix BioPharma Corp. and Moffit Cancer Centre to Present at World Mol...
Helix BioPharma Corp. and Moffit Cancer Centre to Present at World Molecular Imaging Congress Pharmacodynamics of targeted urease and checkpoint blockade using Chemical Exchange Saturation Transfer and 31P-magnetic Resonance Spectroscopy RICHMOND HILL, Ontario, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that they, together with Moffitt Cancer Center (“Moffitt”), will be presenting a poster entitled “Phar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.